Phase 3 Trial of Masitinib Again Enrolling ALS Patients in Norway

Phase 3 Trial of Masitinib Again Enrolling ALS Patients in Norway

304525

Phase 3 Trial of Masitinib Again Enrolling ALS Patients in Norway

A national agency in Norway has given AB Science the go-ahead to resume enrollment in AB19001, a Phase 3 clinical trial investigating the safety and efficacy of the company’s investigational oral therapy masitinib in people with amyotrophic lateral sclerosis (ALS). AB had voluntarily suspended recruitment and treatment  in all its masitinib clinical studies in early June, after data emerged indicating that the medication conferred a potential risk of ischemic heart disease, a condition characterized by recurring chest…

You must be logged in to read/download the full post.